# Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer

> **NIH NIH R01** · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2021 · $574,305

## Abstract

Project Summary/Abstract
The ultimate goal of this mPI proposal is to address a fundamental gap in knowledge on the role of acetyl-CoA
metabolic reprogramming in regulating cyclin E-high ovarian cancer DNA damage response, transformation, and
response to therapy. The results from these studies could have a significant impact on the treatment of the ~20%
of high grade serous ovarian cancer (HGSOC) patients with high cyclin E expression, which are resistant to
emerging PARP inhibitor therapies due to proficiency in homologous recombination (HR)-mediated DNA repair.
This research plan focuses on assessing the experimentally and mechanistically determining the spaciotemporal
metabolic reprogramming of acetyl-CoA on histone hyperacetylation and enhancement of HR-mediated DNA
repair and whether this pathway can be targeted in cyclin E-high HGSOC patients in combination with emerging
PARP inhibitor therapies to obtain a synthetic lethality and sustained therapeutic response. The proposed studies
are based on our preliminary findings that glucose-derived acetyl-CoA is upregulated in cyclin E-high cells,
acetyl-CoA is spatially regulated in the cytoplasm and nucleus, and cyclin E-high cells display hyperacetylation
of histones known to be involved in HR repair. In line with these data, we will explore two overarching scientific
aims: 1) quantitatively dissect acetyl-CoA metabolic reprogramming in cyclin E-high HGSOC and its contribution
to HR-mediated DNA repair; and 2) to determine whether acetyl-CoA mediated epigenetic changes contributes
to ovarian tumorigenesis and therapeutic response. The completion of the scientific aims of this proposal will not
only provide new mechanistic insights into the interplay between the acetyl-CoA-mediated metabolic-epigenetic
axis during ovarian tumorigenesis, but will also establish targeting this axis as a strategy to improve therapeutic
outcome for HGSOC patients with high cyclin E. The proposed research is of high impact because the
mechanistic underpinning of these pathways has the potential to transform the management of HGSOC patients
with high cyclin E. As PARP inhibitors are being developed for many cancer types, studies will have far-reaching
implications for identifying novel strategies to inhibit HR-mediated DNA repair and develop future cancer
therapeutics strategies for a wide range of patients.

## Key facts

- **NIH application ID:** 10182029
- **Project number:** 1R01CA259111-01
- **Recipient organization:** UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- **Principal Investigator:** Katherine Marie Aird
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $574,305
- **Award type:** 1
- **Project period:** 2021-05-01 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10182029

## Citation

> US National Institutes of Health, RePORTER application 10182029, Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer (1R01CA259111-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10182029. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*